Primary Objectives:

• To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable.
• To evaluate the time-course of AD and selected atopic comorbidities.

Secondary Objectives:

• To characterize disease burden and unmet need.
• To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching).
• To document the real-world effectiveness and safety of treatments.

The study duration is 120 months.

Inclusion criteria:

• Patients with moderate to severe AD, according to the Investigator's assessment;
• Currently receiving systemic treatment (including phototherapy) for atopic dermatitis or currently on topical treatment, but otherwise candidates for systemic treatment.

Exclusion criteria:

• Concurrent participation in an interventional clinical trial which modifies patient care.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Pediatric patients with moderate to severe AD whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable.